-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Menopause usually manifests as various mental and physical symptoms, such as hot flashes, sleep disorders, depression, or cognitive dysfunction.
About 80% of menopausal women are affected by such symptoms
.
Sex hormones, especially estrogen, have been shown to have neuroprotective effects, so a decrease in their concentration may contribute to the development of neurodegenerative diseases
Sex hormones, especially estrogen, have been shown to have neuroprotective effects, so a decrease in their concentration may contribute to the development of neurodegenerative diseases
Small-scale studies using various cognitive and radiological measures have shown that hormone therapy has beneficial effects
Researchers included data from general clinics in the UK as QResearch or Clinical Practice Research Data Link (CPRD), using all links to hospital, mortality, and social poverty data
.
From 1998 to 2020, 118,501 women aged 55 and over were initially diagnosed with dementia, matching the age, general practitioner, and index date of the 497416 female control group
diagnosis
The main outcome measure is the diagnosis of dementia from general practitioners, mortality, and hospital records; the odds of menopausal hormone therapy adjusted based on demographics, smoking status, alcohol consumption, comorbidities, family history, and other prescription drugs
.
16,291 (14%) women diagnosed with dementia and 68,726 (14%) control group had used menopausal hormone therapy more than three years before being included in the study
.
In general, no increased risk of dementia associated with menopausal hormone therapy has been observed
In general, no increased risk of dementia associated with menopausal hormone therapy has been observed
Proportion of women receiving hormone therapy by age
Women who have used estrogen-progesterone therapy for 5 to 9 years (1.
11, 1.
04-1.
20) and 10 years or more (1.
19, 1.
06-1.
33) were found to have an increased risk of specific Alzheimer's disease
.
This is equivalent to 5 and 7 additional cases per 10,000 woman-years, respectively
Women who have used estrogen-progestin therapy for 5 to 9 years (1.
In summary, this study estimated the risk of dementia and Alzheimer's disease in women exposed to different types of menopausal hormone therapy, and showed that there was no increase in the risk of dementia in general
references:
Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
Leave a message here
